HR+/HER2- MBC Therapy

CE / CME

Individualizing Therapy for Patients With HR+/HER2- MBC

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Released: December 06, 2024

Expiration: August 06, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 62-year-old woman with a history of stage IIA ER+/HER2- breast cancer that was diagnosed 7 years ago presented recently with persistent back pain for which she has had to take ibuprofen. Previously, she had surgery followed by adjuvant chemotherapy (TC X 4 cycles) and 5 years of adjuvant letrozole completed 2 years ago. Now, imaging shows widespread bone lesions consistent with metastatic breast cancer and supraclavicular lymphadenopathy. Laboratory testing is normal aside from elevated alkaline phosphatase. A node biopsy confirmed ER+/HER2 1+ metastatic breast cancer. Evaluation of ctDNA was notable for lack of ESR1 or PIK3CA mutations.

Which first-line systemic therapy would you recommend?